Andrews, Anne M.

WebsiteHome URL
Semel Institute for Neuroscience, California NanoSystems Institute, Hatos Center for Neuropharmacology

Contact Information

Neuroscience Research Building 507
(310) 794-9421 ­
Neuroscience Research Building 545


Dr. Andrews is Professor of Psychiatry at the University of California, Los Angeles. She is a member of the Semel Institute for Neuroscience & Human Behavior, the Hatos Center for Neuropharmacology, and the California NanoSystems Institute. Dr. Andrews received her B.S. in Chemistry from the Pennsylvania State University and earned her Ph.D. in Chemistry as a U.S. Department of Education Fellow working at the National Institute of Mental Health, where she was later a postdoctoral fellow and senior staff fellow. At the NIMH, Andrews and her mentor, Dr. Dennis Murphy, discovered and characterized a novel serotonin neurotoxin, 2’-NH2-MPTP. Dr. Andrews was also instrumental in early studies on serotonin transporter-deficient mice. Andrews is a member of the Society for Neuroscience, American Chemical Society, and Society for Electroanalytical Chemistry. She has been the recipient of an NIH Fellows Award for Research Excellence, an Eli Lilly Outstanding Young Analytical Chemist Award, an American Parkinson’s Disease Association Research Award, and a Brain & Behavior Research Foundation (NARSAD) Independent Investigator Award. She is a fellow of the Collegium Internationale Neuropsychopharmacologicum and a Serotonin Club elected councilor. Recently, Dr. Andrews became Associate Editor for ACS Chemical Neuroscience.

­At UCLA, Andrews leads efforts in basic and translational research on anxiety and depression, and at the nexus of nanoscience and neuroscience. Andrews’ interdisciplinary research team of neuroscientists, biologists, chemists, and engineers focuses on understanding how the serotonin system and particularly, the serotonin transporter, modulate neurotransmission to influence complex behaviors including anxiety, mood, stress responsiveness, and learning and memory. Genetic and pharmacologic mouse models and human genetic variants are studied to understand the molecular basis of serotonin system function associated with the etiology and treatment of mood and anxiety disorders. Key proteins (e.g., brain-derived neurotrophic factor) and neuronal architectures regulated by serotonin are also investigated. Nanomaterials are designed for fundamental studies on neurotransmitter recognition by native and nonnative binding partners (aptamers) and for the development of in vivo nanobiosensors and functionally directed proteomics.

Research Interest

Serotonin neurotransmitter system







Above:  LLC-PK1 Cells expressing fluorescently-tagged serotonin transporter

Andrews' research group is focused on­­ studying the chemistry of the serotonin neurotransmitter system. The primary goal is to understand more fully the role of serotonin in complex behavior, and the etiology and treatment of psychiatric disorders (depression and anxiety disorders). Genetically engineered mice, as well as selective drugs and neurotoxins are used as tools to investigate normative behavior and disease processes. Neurochemistry in these model systems is interrogated using bioanalytical techniques including high-speed carbon fiber microelectrode voltammetry and in vivo microdialysis coupled to high performance liquid chromatography with electrochemical detection.

Additionally, ELISA, RT-qPCR, autoradiography, and immunocytochemistry are used to investigate neuroadaptive changes in neuronal innervation and the expression of key proteins such as brain-derived neurotrophic factor (BDNF).

Neurotransmitter-functionalized self-assembled monolayer "neurochips" have recently been designed for the development of novel in vivo nanobiosensors and functionally-directed proteomics.





More Publications »